Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis.
Kisley L, Barrett B, Bauer A, Dwyer-Nield L, Barthel B, Meyer A, Thompson D, Malkinson A. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Research 2002, 62: 6850-6. PMID: 12460898.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsButylated HydroxytolueneCarcinogensEndothelial Growth FactorsImmunohistochemistryIntercellular Signaling Peptides and ProteinsLungLung NeoplasmsLymphokinesMacrophages, AlveolarMaleMiceMice, KnockoutNitric OxideNitric Oxide SynthaseNitric Oxide Synthase Type IIUrethaneVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsLung tumor multiplicityLung tumorigenesisLung tumorsMouse lung tumorigenesisINOS deficiencyINOS (-/-) miceNitric oxideLung inflammationTumor multiplicityLung cancer chemopreventive agentNitric oxide synthase contentInducible nitric oxide synthaseInducible nitric oxide synthase (iNOS) contentMurine lung tumorigenesisVascular endothelial growth factor (VEGF) expressionChronic lung inflammationRole of iNOSLung cancer patientsWhole lung extractsCOX-2 contentAlveolar macrophage infiltrationNitric oxide synthaseWild-type miceBronchiolar Clara cellsMouse lung tumorsCelecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice
Kisley L, Barrett B, Dwyer-Nield L, Bauer A, Thompson D, Malkinson A. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 2002, 23: 1653-1660. PMID: 12376474, DOI: 10.1093/carcin/23.10.1653.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsLung tumor formationPulmonary inflammationLung tumorigenesisLung tumorsMacrophage infiltrationPGE2 productionTumor formationMice fed control dietCOX-2-specific inhibitorsTwo-stage carcinogenesis protocolCelecoxib-treated miceLung cancer developmentAnti-inflammatory drugsProduction of eicosanoidsFed control dietCyclooxygenase-enzyme expressionDifferent organ systemsChronic administrationPGE2 levelsVascular leakageClinical trialsCarcinogenesis protocolMurine modelHigh risk